Business Context and Reporting Period
This Form 8-K Current Report was filed by Vanda Pharmaceuticals Inc. on October 23, 2007. The filing discloses significant changes in executive leadership, specifically the appointment of a new Senior Vice President and Chief Commercial Officer and the termination of the Vice President for Regulatory Affairs.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements and personnel changes.
Material Changes
- Appointment: Al Gianchetti was appointed as Senior Vice President and Chief Commercial Officer, effective October 25, 2007. He brings over 18 years of experience from GlaxoSmithKline.
- Termination: Thomas Copmann, Ph.D., Vice President for Regulatory Affairs, terminated his employment on October 24, 2007.
Compensation and Equity Details
The filing details the compensatory arrangements for Mr. Gianchetti:
- Base Salary: $295,000 annually.
- Signing Bonus: $100,000.
- Retention Bonus: $35,000 upon completion of one year of continuous service.
- Annual Incentive: Target bonus equal to 25% of base salary.
- Stock Options: 90,000 shares at an exercise price of $16.24 per share. Vesting schedule includes 25% after 12 months, with the remainder vesting monthly over the next three years.
- Restricted Stock: 3,000 shares vesting in four equal annual installments.
- Indemnification: An agreement was entered into to indemnify Mr. Gianchetti to the fullest extent permitted under Delaware law.
Investor Verification Checklist
- Verify the impact of the departure of the Vice President for Regulatory Affairs on the company's drug development pipeline.
- Confirm the vesting acceleration provisions regarding change in control for the new executive's equity awards.
- Review the company's cash position to ensure it can support the immediate cash outflows associated with the $135,000 in signing and retention bonuses.
- Check subsequent filings for updates on the recruitment of a replacement for the Regulatory Affairs role.